Gabe Ortiz, MD, PhD

Professor

Gabriel Ortiz, MD, PhD, is an Associate Clinical Professor at UCSF and a hospitalist at Zuckerberg San Francisco General. As the Medical Director of the Medical-Surgical Care Areas, he is focused on quality improvement work to enhance the care delivered to the vulnerable communities served by ZSFG. He is deeply engaged in applying Toyota's LEAN production and LEAN daily management systems as tools for achieving healthcare systems transformation (see links below for more information). Dr. Ortiz is also engaged in the implementation and optimization of Epic, the new enterprise EHR at ZSFG.
Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 2012 - Infectious Diseases, UCSF
Chief Residency, 2008 - Internal Medicine, UCSF
Residency, 2007 - Internal Medicine, UCSF
MD, PhD, 2004 - Medicine and Human Immunology, Tri-Institutional MD, PhD Program
MS, BS, 1996 - Molecular Biophysics and Biochemistry, Yale Univeristy
Publications
  1. Hidden
    Journal of hospital medicine

    Rosenthal MA, Ranji SR, Kanzaria HK, Ortiz GM, Chase J, Chodos AH, Nguyen OK, Rodriguez EG, Makam AN. Characterizing patients hospitalized without an acute care indication: A retrospective cohort study. Journal of hospital medicine 2023. PMID: 36757173


  2. Hidden
    NEJM Catalyst

    Dana Freiser, BS, BA, RN, Merjo Roca, BA, RN, Tony Chung, PharmD,
    Tanvi Bhakta, MSN, RN, CNL, Lisa G. Winston, MD, Gabriel M. Ortiz, MD, PhD. The Evolution of a Hospital-Based Covid-19 Vaccination Program for Inpatients NEJM Catalyst 2022. PMID:


  3. Hidden
    "Are Telehealth Visits Feasible for Vulnerable Patients?"

    Weiner J, Suwalski P, Holtgrewe M, Rakitko A, Thibeault C, Müller M, Patriki D, Quedenau C, Krüger U, Ilinsky V, Popov I, Balnis J, Jaitovich A, Helbig ET, Lippert LJ, Stubbemann P, Real LM, Macías J, Pineda JA, Fernandez-Fuertes M, Wang X, Karadeniz Z, Saccomanno J, Doehn JM, Hübner RH, Hinzmann B, Salvo M, Blueher A, Siemann S, Jurisic S, Beer JH, Rutishauser J, Wiggli B, Schmid H, Danninger K, Binder R, Corman VM, Mühlemann B, Arjun Arkal R, Fragiadakis GK, Mick E, Comet C, Calfee CS, Erle DJ, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Langelier CR, Venkataramani U, García F, Zyla J, Drosten C, Alice B, Jones TC, Suttorp N, Witzenrath M, Hippenstiel S, Zemojtel T, Skurk C, Wolfgang P, Borodina T, Pa-Covid SG, Ripke S, Sander LE, Beule D, Landmesser U, Guettouche T, Kurth F, Heidecker B. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34490415


  4. Hidden
    "Are Telehealth Visits Feasible for Vulnerable Patients?"

    Sarma A, Christenson SA, Byrne A, Mick E, Pisco AO, DeVoe C, Deiss T, Ghale R, Zha BS, Tsitsiklis A, Jauregui A, Moazed F, Detweiler AM, Spottiswoode N, Sinha P, Neff N, Tan M, Serpa PH, Willmore A, Ansel KM, Wilson JG, Leligdowicz A, Siegel ER, Sirota M, DeRisi JL, Matthay MA, COMET Consortium, Hendrickson CM, Kangelaris KN, Krummel MF, Woodruff PG, Erle DJ, Calfee CS, Langelier CR. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34446707


  5. Hidden
    "Are Telehealth Visits Feasible for Vulnerable Patients?"

    van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Le Voyer T, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ, UCSF COMET consortium. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 34429372


  6. Hidden
    "Are Telehealth Visits Feasible for Vulnerable Patients?"

    van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Mann SA, Lynch KL, Yun C, Havlir DV, Chamie G, Marquez C, Greenhouse B, Lionakis MS, Norris PJ, Dumont LJ, Kelly K, Zhang P, Zhang Q, Gervais A, Voyer TL, Whatley A, Si Y, Byrne A, Combes AJ, Rao AA, Song YS, UCSF COMET consortium, Fragiadakis GK, Kangelaris K, Calfee CS, Erle DJ, Hendrickson C, Krummel MF, Woodruff PG, Langelier CR, Casanova JL, Derisi JL, Anderson MS, Ye CJ. Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2021. PMID: 33758859


  7. Hidden
    JAMA internal medicine

    Haber LA, Erickson HP, Ranji SR, Ortiz GM, Pratt LA. Acute Care for Patients Who Are Incarcerated: A Review. JAMA internal medicine 2019. PMID: 31524937


  8. Hidden
    Cureus

    Devendra GP, Ortiz GM, Haber LA. By the Light of Day: Quality, Safety, and Education During the Overnight Admission Handoff. Cureus 2019. PMID: 31263637


  9. Hidden
    JAMA internal medicine

    Rosendale N, Goldman S, Ortiz GM, Haber LA. Acute Clinical Care for Transgender Patients: A Review. JAMA internal medicine 2018. PMID: 30178031


  10. Hidden
    Case reports in infectious diseases

    Block BL, Mehta T, Ortiz GM, Ferris SP, Vu TH, Huang L, Cattamanchi A. Unusual Radiographic Presentation of Pneumocystis Pneumonia in a Patient with AIDS. Case reports in infectious diseases 2017. PMID: 29362681


  11. Hidden
    Journal of hospital medicine

    Haber LA, Ortiz GM. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. Journal of hospital medicine 2014. PMID: 25352497


  12. Hidden
  13. Hidden
    PloS one

    Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. Volume 8 of Issue 12. PloS one 2013. PMID: 24391889


  14. Hidden
    Molecular & cellular proteomics : MCP

    Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Molecular & cellular proteomics : MCP 2012. PMID: 22580588


  15. Hidden
    AIDS research and human retroviruses

    Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS research and human retroviruses 2006. PMID: 16438646


  16. Hidden
    Journal of acquired immune deficiency syndromes (1999)

    Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. Journal of acquired immune deficiency syndromes (1999) 2004. PMID: 15213562


  17. Hidden
    Journal of acquired immune deficiency syndromes (1999)

    Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. Journal of acquired immune deficiency syndromes (1999) 2003. PMID: 14657757


  18. Hidden
    Journal of virology

    Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. Journal of virology 2003. PMID: 12767994


  19. Hidden
    AIDS (London, England)

    García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS (London, England) 2003. PMID: 12478068


  20. Hidden
    AIDS (London, England)

    Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS (London, England) 2002. PMID: 12441810


  21. Hidden
    Journal of virology

    Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. Journal of virology 2002. PMID: 11739706


  22. Hidden
    Proceedings of the National Academy of Sciences of the United States of America

    Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proceedings of the National Academy of Sciences of the United States of America 2001. PMID: 11687611


  23. Hidden
    AIDS (London, England)

    García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS (London, England) 2001. PMID: 11416735


  24. Hidden
    AIDS (London, England)

    Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS (London, England) 2000. PMID: 11089619


  25. Hidden
    The Journal of infectious diseases

    Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. The Journal of infectious diseases 2000. PMID: 10950770


  26. Hidden
    The Journal of infectious diseases

    Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. The Journal of infectious diseases 2000. PMID: 10762561


  27. Hidden
    The Journal of clinical investigation

    Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. The Journal of clinical investigation 1999. PMID: 10491418


  28. Hidden
    Journal of lipid research

    Johnson WJ. Cell-free transfer of cholesterol from lysosomes to phospholipid vesicles. Journal of lipid research 1996. PMID: 8820102


  29. Hidden
    Biochemical pharmacology

    Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochemical pharmacology 1975. PMID: 10


  30. Hidden
    Arzneimittel-Forschung
  31. Hidden
    International ophthalmology clinics
  32. Hidden
    “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org

    Gabriel M. Ortiz and David Graham. “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org “Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org . PMID: